GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kintor Pharmaceutical Ltd (HKSE:09939) » Definitions » Accounts Receivable

Kintor Pharmaceutical (HKSE:09939) Accounts Receivable : HK$0.00 Mil (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Kintor Pharmaceutical Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Kintor Pharmaceutical's accounts receivables for the quarter that ended in Dec. 2023 was HK$0.00 Mil.

Accounts receivable can be measured by Days Sales Outstanding.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Kintor Pharmaceutical's Net-Net Working Capital per share for the quarter that ended in Dec. 2023 was HK$0.11.


Kintor Pharmaceutical Accounts Receivable Historical Data

The historical data trend for Kintor Pharmaceutical's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kintor Pharmaceutical Accounts Receivable Chart

Kintor Pharmaceutical Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Accounts Receivable
Get a 7-Day Free Trial - - - - -

Kintor Pharmaceutical Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Accounts Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Kintor Pharmaceutical Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.


Kintor Pharmaceutical Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Kintor Pharmaceutical's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Kintor Pharmaceutical's accounts receivable are only considered to be worth 75% of book value:

Kintor Pharmaceutical's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2023 is calculated as:

Net-Net Working Capital Per Share
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(498.215+0.75 * 0+0.5 * 0-449.674
-0-0)/429.849
=0.11

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.


Kintor Pharmaceutical Accounts Receivable Related Terms

Thank you for viewing the detailed overview of Kintor Pharmaceutical's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Kintor Pharmaceutical Business Description

Traded in Other Exchanges
Address
No. 20 Songbei Road, Suzhou Industrial Park, Jiangsu, Suzhou, CHN, 215123
Kintor Pharmaceutical Ltd is a clinical-stage novel drug developer in China focused on the proprietary R&D of drugs for cancers and other AR-related diseases. The company's drug candidate, Pruxelutamide, is a drug undergoing phase III clinical trials in China and phase III clinical trials in the United States for mCRPC as well as clinical trials for breast cancer. Its pipeline of seven drug candidates includes Pruxelutamide (GT0918), Pyrilutamide (KX-826), ALK-1 (GT90001), Detorsertib (GT0486), Hedgehog/SMO Inhibitor (GT1708F), PD-L1/TGF-ß (GT90008), and AR-PROTAC Compound (GT20029). It operates in a single segment focusing on the research and development of medical products.
Executives
Tong Youzhi 2101 Beneficial owner
Kt International Investment Limited 2101 Beneficial owner
Guo Chuangxing 2201 Interest of corporation controlled by you
Kg Development Limited 2101 Beneficial owner
Nomura Holdings, Inc. 2201 Interest of corporation controlled by you
Tong Youzhi 2201 Interest of corporation controlled by you
Zhu Hai Ge Li Jin Rong Tou Zi Guan Li You Xian Gong Si 2101 Beneficial owner
Zhu Hai Ge Li Ji Tuan You Xian Gong Si 2201 Interest of corporation controlled by you
Sovereign Fiduciaries (hong Kong) Limited
Kiya Company Limited
Lian Xiang Kong Gu Gu Fen You Xian Gong Si 2201 Interest of corporation controlled by you
Nan Ming You Xian Gong Si 2201 Interest of corporation controlled by you
Shi Xian You Xian Gong Si 2101 Beneficial owner

Kintor Pharmaceutical Headlines

No Headlines